Vectra DA: A Better Measure for Predicting Radiographic Progression in Rheumatoid Arthritis?
|
|
- Roxanne Cox
- 6 years ago
- Views:
Transcription
1 Vectra DA: A Better Measure for Predicting Radiographic Progression in Rheumatoid Arthritis? Ronald F. van Vollenhoven, MD, PhD Jonathan Kay, MD Andrew Laster MD, FACR Eric Sasso, MD Crescendo Bioscience is the sponsor of the presentation. 1
2 Agenda Introduction: - Eric Sasso, MD, Crescendo Bioscience The Role of CRP and ESR in Assessing RA Disease Activity: - Jonathan Kay, MD, UMass Medical School Vectra DA and Radiographic Progression: - Eric Sasso, MD, Crescendo Bioscience - Ronald van Vollenhoven, MD, PhD, Karolinska Institute Clinical Applications of Vectra DA: - Andrew Laster, MD, FACR, Arthritis & Osteoporosis Consultants of the Carolinas Q&A 2
3 Vectra DA Intended Use Vectra DA, a multi-biomarker blood test, was validated to measure disease activity in adults diagnosed with rheumatoid arthritis Test results are intended to Aid in the assessment of disease activity in RA patients Help inform patient management decisions when used in conjunction with standard clinical assessment This test is not intended or validated to: Diagnose RA Guide therapy selection Interpretation of individual biomarker results has not been validated 3
4 Vectra DA Biomarkers: Twelve biomarkers reflect the heterogeneity of RA Biomarker Biomarker Category VCAM-1 EGF VEGF-A IL-6 TNF-RI MMP-1 MMP-3 Adhesion Molecules Growth Factors Cytokine-related Proteins Matrix Metalloproteinases Primary Role Cellular influx and tissue expansion Local inflammation and destruction Cartilage degradation and joint damage YKL-40 Skeletal-related Proteins Stromal activity & regulation (fibroblasts, chondrocytes, vascular cells) Leptin Resistin SAA CRP Hormones Acute Phase Proteins Systemic Inflammatory Response 4
5 An algorithm is applied to the concentrations of individual biomarkers to calculate a Vectra DA score from 1 to 100 * The range reflects the precision of the score based on repeat measurements. 5
6 The Role of CRP and ESR in Assessing RA Disease Activity Jonathan Kay, MD UMass Medical School Crescendo Bioscience is the sponsor of the presentation. 6
7 Disclosures Research Support: AbbVie Inc.; Ardea Biosciences, Inc.; Eli Lilly and Company; Fidia Farmaceutici, SpA; Roche Laboratories, Inc. Consultant: AbbVie Inc.; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Celgene Corp.; Crescendo Bioscience, Inc.; Eli Lilly and Company; EPIRUS Biopharmaceuticals, Inc.; Genentech Inc.; Hospira, Inc.; Janssen Biotech, Inc.; medac pharma Inc.; PanGenetics, B.V.; Pfizer Inc.; Roche Laboratories, Inc.; Sun Pharmaceutical Industries Ltd.; UCB, Inc. 7
8 8
9 Background Patients with active RA often have elevated tender & swollen joint counts and patient & MD global assessment, yet have normal ESR and/or CRP These discordances imply that when ESR and CRP are in the normal range, they may be uninformative in clinical practice, especially for patients with active RA These discordances also imply that patients may fail to meet clinical trial APR entry criteria despite having active disease. 1 1 Sokka T, Pincus T. Arthritis Rheum. 2003; 48:
10 Study Overview Observational study CORRONA database October 1, 2001 through February 27, RA patients with active disease All had CDAI >2.8 at a visit ESR and CRP obtained at visit 4,031 (44.1%) were biologic-naïve Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 10
11 Baseline Characteristics by APR Levels Neither APR elevated n=2520 APR levels discordant n=1058 Both APR elevated n=650 P-Value Age (years) 59.29± ± ± < Duration of RA (years) 11.01± ± ± CDAI ± ± ± < Tender Joints 3.73 ± ± ± 7.21 <0.0001* Swollen Joints 4.04 ± ± ± 6.42 <0.0001* Patient Global Assessment ± ± ± < MD Global Assessment ± ± ± < Prednisone Use 680 (26.98%) 341 (32.23%) 275 (42.31%) < Methotrexate Use 1668 (66.19%) 698 (65.97%) 417 (64.15%) Biologic Use 1263 (50.12%) 447 (42.25%) 224 (34.46%) < * Log-linear model (Poisson) - χ² test Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 11
12 ESR and CRP were each low in ~70% of patients Data from 9,135 patients with active RA (CDAI >2.8) from the CORRONA registry 29% CRP >0.8* n = 2,628 71% CRP 0.8* n = 6,507 30% ESR >28* n = 2,719 70% ESR 28* n = 6,416 * Units of CRP are mg/dl; Units of ESR are mm/hr Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 12
13 CRP and ESR were both low in 58% of patients with active RA Data from 9,135 patients with active RA (CDAI >2.8) from the CORRONA registry 42% ESR >28* and/or CRP >0.8* n = 3,840 58% ESR 28* and CRP 0.8* n = 5,295 * Units of CRP are mg/dl; Units of ESR are mm/hr Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 13
14 Similar levels of low CRP and ESR were seen among the 4,031 biologic-naïve patients with active RA (CDAI >2.8) 34% CRP >0.8* n = 1,357 66% CRP 0.8* n = 2,674 32% ESR >28* n = 1,275 68% ESR 28* n = 2,756 * Units of CRP are mg/dl; Units of ESR are mm/hr Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 14
15 Similar levels of low CRP and ESR were seen among the 4,031 biologic-naïve patients with active RA (CDAI >2.8) 46% ESR >28* and/or CRP >0.8* n = 1,867 54% CRP 0.8* and ESR 28* n = 2,164 * Units of CRP are mg/dl; Units of ESR are mm/hr Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 15
16 In both moderate and high CDAI Disease Activity Levels, both ESR and CRP were low in ~50% of patients 100% 90% 80% 70% 60% 10% 23% 16% 27% 26% 28% Both CRP and ESR elevated 50% 40% 30% 20% 67% 57% 46% Either CRP or ESR elevated Neither CRP or ESR elevated 10% 0% CDAI LDA MDA HDA CDAI LDA CDAI MDA CDAI HAD (>2.8 & 10) (>10 & 22) (>22) LDA = Low Disease Activity, MDA = Moderate Disease Activity, HDA = High Disease Activity Kay J, Morgacheva O, Messing S, et al. Arthritis Research & Therapy 2014; 16(1) 16
17 Summary Patients with active RA often have elevated tender & swollen joint counts and patient & MD global assessment, yet have normal ESR and/or CRP These discordances imply that when ESR and CRP are in the normal range, they may be uninformative in clinical practice, especially for patients with active RA These discordances also imply that patients may fail to meet clinical trial APR entry criteria despite having active disease. 1 1 Sokka T, Pincus T. Arthritis Rheum. 2003; 48:
18 Percentage of Assessments Multiple Cohorts ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Vectra DA algorithm scores were frequently moderate or high when CRP was low ( 1 mg/dl) 100% 90% 13% 13% 80% 70% 60% 50% 40% 30% 20% 10% 0% 59% 34% 7% SWEFOT SWEFOT era era Pre-MTX Pre-MTX N = 71/ % 54% 33% Leiden Leiden Stable Stable DMARDs DMARDs N = 158/ % 36% 51% BRASS Stable Therapy Stable BRASS Therapy N = 184/ % Vectra DA algorithm score High (>44) Mod (30-44) Low (<30) Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; Lee, YC. et al, ACR 2013, Arthritis Rheum 2013;65 Suppl 10:2683; Li W, et al, EULAR 2013, poster # FRI0098; Data on File * The Vectra DA algorithm and biomarkers were used in a study performed in Crescendo s R&D lab 18
19 Percentage of Assessments SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Vectra DA algorithm scores were also frequently moderate or high when ESR was low ( 25) 100% Low CRP Low ESR 90% 80% 70% 60% 50% 40% 30% 20% 59% 34% 68% 26% Vectra DA algorithm score High (>44) Mod (30-44) Low (<30) 10% 0% 7% 7% SWEFOT SWEFOT era era Pre-MTX SWEFOT Leiden Stable era DMARDs Pre-MTX BRASS Stable Therapy N = 71/ % N = 74/ % Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; ; Crescendo Data on File SWEFOT: CRP groups are based on CRP values from clinical laboratory 19
20 Vectra DA and Radiographic Progression Eric Sasso, MD Crescendo Bioscience Ronald F. van Vollenhoven, MD, PhD Karolinska Institute Crescendo Bioscience is the sponsor of the presentation. 20
21 Disclosures Dr. Eric Sasso is an employee of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. 21
22 Leiden Stable DMARDs Crescendo Bioscience is the sponsor of the presentation. 22
23 Stable DMARDS / Leiden ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Leiden study N=271 visits for 163 patients Clinic visit On DMARDs 1 year Clinical data Vectra DA X-ray #1 X-ray #2 Radiographic progression van der Helm-van Mil, et al. Rheumatology (5):
24 Δ SHS > 3 in a 12 month period Stable DMARDS / Leiden ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Vectra DA algorithm score discriminated risk for radiographic progression better than DAS28-CRP Vectra DA Algorithm Score DAS28-CRP RR = 6.1 P<0.05 RR = 1.8 N = 271 visits, 163 patients 50% 40% 43% 37% 30% 20% 15% 18% 20% 27% 24% 10% 7% 0% n = 3/43 Vectra DA 2/13 Algorithm 19/105 Score 47/110 n = 17/83 8/30 DAS28CRP 23/95 23/63 Range = 25 (Remission ; High >44) <2.3 (Remission 2.3 <2.32; to >2.7 High to >4.1) Remission Low Moderate High van der Helm-van Mil, et al. Rheumatology doi: /rheumatology/kes378 The Vectra DA algorithm and biomarkers were used in a study performed in Crescendo s R&D lab 24
25 Stable DMARDS / Leiden Good radiographic outcome (ΔSHS 3) for patients in remission versus non-remission Definition of Remission Remission Nonremission P-value PLR DAS28-CRP < % (66/83) 71% (134/188) ACR/EULA R 83 (25/30) 73 (175/241) Vectra DA (40/43) 70 (160/228) van der Helm-van Mil, et al. Rheumatology (5):
26 Stable DMARDS / Leiden Good radiographic outcome (ΔSHS 3) for patients in remission versus non-remission Definition of Remission Remission Nonremission P-value PLR DAS28-CRP < % (66/83) 71% (134/188) ACR/ EULAR 83% (25/30) 73% (175/241) Vectra DA (40/43) 70 (160/228) van der Helm-van Mil, et al. Rheumatology (5):
27 Stable DMARDS / Leiden Good radiographic outcome (ΔSHS 3) for patients in remission versus non-remission Definition of Remission Remission Nonremission P-value PLR DAS28-CRP < % (66/83) 71% (134/188) ACR/ EULAR 83% (25/30) 73% (175/241) Vectra DA 25 93% (40/43) 70% (160/228) van der Helm-van Mil, et al. Rheumatology (5):
28 Stable DMARDS / Leiden Good radiographic outcome (ΔSHS 3) for patients in remission versus non-remission Definition of Remission Remission Nonremission P-value PLR DAS28-CRP < % (66/83) 71% (134/188) ACR/ EULAR 83% (25/30) 73% (175/241) Vectra DA 25 93% (40/43) 70% (160/228) van der Helm-van Mil, et al. Rheumatology (5):
29 Vectra DA and Radiographic Progression Ronald F. van Vollenhoven, MD, PhD Karolinska Institute Crescendo Bioscience is the sponsor of the presentation. 29
30 Disclosures Research support, consultancy: AbbVie, Biotest, BMS, Crescendo, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, Vertex 30
31 31
32 era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted SWEFOT Vectra DA Analysis Overview Patients from 15 rheumatology units in Sweden Early rheumatoid arthritis (era) patients with disease duration <1 year, DMARD nai ve X-ray #1 Clinical Data Vectra DA (N = 235) Assess Response ΔSHS X-ray #2 BL month 3 year 1 Start MTX R NR MTX MTX/H/S MTX/Inf R = Responders NR = Non Responders MTX/H/S = Methotrexate with sulfasalazine and hydroxychloroquine MTX/Inf = Methotrexate with infliximab Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; 32
33 % Rapid Radiographic Progressors (Δ SHS >5 BL to year 1) era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Vectra DA categories predicted risk of rapid radiographic progression (ΔSHS >5) over 1 year 35% 30% 25% 20% 21% 15% 10% 5% 0% n = 3% 0% 0/5 1/29 42/201 Low Moderate High (<30) (30-44) (>44) Vectra DA Score at Baseline (Total N = 235) Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; 33
34 % Rapid Radiographic Progressors (Δ SHS >5 BL to year 1) era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Vectra DA categories predicted risk of rapid radiographic progression (ΔSHS >5) over 1 year 35% 30% 25% 20% 15% p = x Relative Risk 21% 10% 5% 0% n = 3% 0% 0/5 1/29 42/201 Low Moderate High (<30) (30-44) (>44) Vectra DA Score at Baseline (Total N = 235) Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; Data on File The p value represents low/moderate vs. high Vectra DA score. The p value for moderate vs. high Vectra DA score is (figure 2D) 34
35 Δ Total Sharp-van der Heijde Score era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Baseline Vectra DA score categories differentiated radiographic progressors at 1 year BL Vectra DA Levels High (> 44), n = 201 Moderate (30 44), n = 29 Low (< 30), n = 5 ΔSHS>5 21% 3% 0% 5 ΔSHS>5 Cumulative % of Patients N=235 Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; 35
36 Δ Total SHS Δ Total SHS era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Baseline Vectra DA score differentiated radiographic progressors at year 1 better than baseline CRP, ESR, or DAS28-ESR Δ Total SHS Δ Total SHS Vectra DA category High (> 44), n = 201 Cumulative % of Patients DAS28-ESR category High (>5.1), n = 167 Moderate (> ), n = 68 Low High ( (>5.1), 3.2), n = 0167 ΔSHS>5 Moderate High (> 44), (30 n = 44), 201 n = 29 21% Low Moderate (< 30), (30 n = 544), n = 29 3% Low (< 30), n = 5 0% 5 5 ΔSHS>5 20% Moderate (> ), n = 68 15% Low ( 3.2), n = 0 CRP category High (> 3 mg/dl), n = 89 Moderate (> 1-3 mg/dl), n = 75 High (> 3 mg/dl), n = 89 Low ( 1 mg/dl), 71 Moderate (> 1-3 mg/dl), n = 75 Cumulative % of Patients 3 rd Tertile (>44 mm/h), n = 80 2 nd Tertile (>25-45 mm/h), n = 81 3 rd 1 st Tertile (>44 ( 25 mm/h), mm/h), n = n 80 = 74 ESR category ΔSHS>5 25% 15% Low ( 1 mg/dl), n = 71 14% 2 nd Tertile (>25-45 mm/h), n = 81 1 st Tertile ( 25 mm/h), n = 74 ΔSHS>5 26% 15% 14% 5 5 Cumulative % of Patients N=235 Cumulative % of Patients SHS = Sharp-van der Heijde Score Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; 36
37 Number of Patients era Pre-MTX / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Rapid radiographic progression at 1 year in patients with high Vectra DA (>44) was observed across CRP categories at baseline Baseline Vectra DA Score Baseline Vectra DA Low (<30) Mod ΔSHS (30 >5 (n 44) = 43) High (>44) ΔSHS >5 at 1 year Low ( 1) Mod (>1 3) High (>3) n = 71 n = 75 n = 89 Baseline CRP (mg/dl) Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Annals of the Rheumatic Diseases doi: /annrheumdis ; 37
38 Rapid Radiographic Progressors (Δ SHS > 5) from Year 1 to 2 era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Persistence of a high Vectra DA score at Year 1 was associated with rapid progression from Year 1 to Year 2 (ΔSHS >5) Among Patients with High Vectra DA at Baseline 40% 35% 30% 20% 10% 4% 6% n = 0% N= 51 DAS28CRP (Remission <2.32; High >4.1) Low Moderate High Vectra DA Score at Year 1 Patients had high Vectra DA score at BL and were MTX non-responders at Month 3. Rapid radiographic progression is defined as ΔSHS >5 in one year. Hambardzumyan, K. Ann Rheum Dis 2014;73(Suppl2). 38
39 Vectra DA is not validated to guide therapy selection. The statements/conclusions provided herein are based on a secondary analysis of the SWEFOT trial data. Additional validation studies would be required to support use of Vectra DA as a predictor of therapy response. 39
40 Patients with DAS at year 1 era / SWEFOT ML-ACR2014ITSlides-01 11/14 unauthorized changes not permitted Response to triple therapy was best following a large decrease in Vectra DA score (>20) on MTX monotherapy 80% Triple therapy Anti-TNF 70% 67% 60% 57% 50% 40% 43% 37% 30% 20% 10% 0% n = 12/18 19/44 6/16 29/51 Δ >20 Δ 20 Δ >20 Δ 20 Δ Vectra DA at month 3 of MTX Vectra DA is not validated to guide therapy selection. The statements/conclusions provided herein are based on a secondary analysis of the SWEFOT trial data. Additional validation studies would be required to support use of Vectra DA as a predictor of therapy response. Hambardzumyan, K. Ann Rheum Dis 2014;73(Suppl2). 40
41 Clinical Applications of Vectra DA Andrew Laster MD, FACR Arthritis & Osteoporosis Consultants of the Carolinas Charlotte, NC Crescendo Bioscience is the sponsor of the presentation. 41
42 Disclosures Advisory board: Amgen, Crescendo Bioscience, Genentech/ Roche, Lilly, UCB Speakers Bureau: Abbvie, Amgen, Crescendo Bioscience, Genentech/ Roche, GSK, Lilly, UCB Consultant: Augmedix, Hologic, Medimaps 42
43 Arthritis & Osteoporosis Consultants of the Carolinas Community based independent rheumatology practice in Charlotte, NC (pop.1.5 x 10 6 ) 6 rheumatologists / 2 NPs / 41 total staff Single office Full capability with X ray and U/S MRI not available in office without CON in NC 43
44 Use of Vectra DA in My Practice Number of RA patients in practice: 456 Tested with Vectra DA in Last 12 Months: 322 (71%) Single test 52% > 1 test 48% Score Distribution for Last 12 Months Score Composite for Last 12 Months 30% 25% 20% 15% 10% 5% 0%
45 Why Not Just Rely on the Clinical Exam? 12-30% of patients with apparent clinical remission have evidence of radiographic progression 1,2,3 Advanced imaging with U/S or MRI: has superior sensitivity compared to clinical evaluation for detecting synovitis correlates with subsequent X ray damage and functional outcome ~ 60% of patients not in clinical remission do not progress radiographically 2 1 Brown et al Arthritis Rheum 2008; 58(10): Lillegraven et al Ann Rheum Dis 2012; 71(50): van der Helm-van Mil et al Rheumatology 2013; 52 (5):
46 Vectra DA: How I incorporate into practice Clinical Exam Role of Vectra Comments Normal joint exam Synovitis on exam and no radiographic abnormalities (erosions/jsn) Synovitis on exam + erosions and/or JSN Tender joints without obvious synovitis Rule out subclinical synovitis Assess likelihood of radiographic progression Helps assess adequacy of response to therapy Helps assess patients with co-morbidities (Fibromyalgia / OA) If ESR/CRP are normal, an elevated Vectra DA score may lead to U/S or MRI to confirm active RA Low Vectra DA score means lower risk of progression. High Vectra DA score means higher risk of progression. Clinical measures and ESR/CRP may not be sufficient in assessing LDA or remission. Low Vectra DA means active RA is less likely 46
47 Other Possible Roles for Vectra DA Monitor response to drug therapy: MTX +/- corticosteroids Biologic therapy: abatacept, adalimumab, etanercept, golimumab, infliximab, tocilizumab* tofacitinib Insurance approval: Biologic dosing: adalimumab, tofacitinib Assessment of disease activity in single joint instead of MRI * Change in Vectra DA score during tocilizumab treatment may underestimate the change in clinical response 47
48 Summary: Clinical Utility of Vectra DA in My Practice Vectra DA has had a significant impact on my ability to better assess disease activity in RA patients with a variety of presentations (there is not one ideal patient type where Vectra DA is best suited): Identify patients with sub-clinical synovitis Exclude active RA in setting of co-morbidities Assess early in disease course, likelihood of progression with radiographic damage Vectra DA has resulted in more selective utilization of advanced diagnostic imaging in my practice Vectra DA has allowed me to more confidently manage drug therapy in a treat-to-target approach 49
49 Q&A Crescendo Bioscience is the sponsor of the presentation. 50
50 Vectra DA Posters and Presentations at ACR Oral Presentations Wednesday, Nov. 19; Room 258B 9:30 9:45 AM 2973 The Multi-Biomarker Disease Activity Score as a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis; E.H. Sasso, G. Wu, C.C. Hwang, M.E. Weinblatt, N.A. Shadick,C. Alexander, O.G. Segurado 9:45 10:00 AM 2974 Multi-Biomarker Disease Activity Score is Associated with Power Doppler Ultrasound in Patients with Rheumatoid Arthritis in Low Disease Activity State; M.H. Ma, T. Garrood, W. Li, N.A. Defranoux, G.H. Kingsley, A.P. Cope, D. Scott Poster Presentations Sunday, Nov 16, 9:00 11:00 AM; Exhibit Hall B 364 In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points is Predictive of Subsequent Radiographic Progression; K. Hambardzumyan R.J. Bolce, S. Saevarsdottir, K. Forslind, I.F. Petersson, P. Geborek, E.H. Sasso, D. Chernoff, S. Cruickshank, R.F. van Vollenhoven 367 In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi- Biomarker Disease Activity Score is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy; K. Hambardzumyan, R.J. Bolce, S. Saevarsdottir, K. Forslind, I.F. Petersson, P. Geborek, E.H. Sasso, D. Chernoff, S. Cruickshank, R.F. van Vollenhoven 376 Using the Multi-Biomarker Disease Activity Score as a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment; R.F. van Vollenhoven, R. Bolce, K. Hambardzumyan, S. Saevarsdottir, K. Forslind, I.F. Petersson, E.H. Sasso, C.C Hwang, O.G. Segurado, P. Geborek Tuesday, Nov. 18; 9:00 11:00 AM Exhibit Hall B 2615 Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis; W.P. Maksymowych, S. Wichuk, P.S. Eastman, E.H. Sasso 51
Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis
Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis O.G. Segurado, E.H. Sasso Crescendo Bioscience, South San Francisco, United States. Oscar G. Segurado,
More informationVectra DA Blood Test for Rheumatoid Arthritis
Medical Policy Manual Laboratory, Policy No. 67 Vectra DA Blood Test for Rheumatoid Arthritis Next Review: June 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER Medical Policies
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationORIGINAL ARTICLE. Rheumatoid arthritis
To cite: Hambardzumyan K, Bolce RJ, Saevarsdottir S, et al. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results
More informationVectra DA Blood Test for Rheumatoid Arthritis
Vectra DA Blood Test for Rheumatoid Arthritis Policy Number: 2.04.119 Last Review: 4/2018 Origination: 4/2016 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More information10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria
Randomization (1:1:1:1) /28/13 Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes
More informationMultibiomarker Disease Activity Blood Test for Rheumatoid Arthritis
Multibiomarker Disease Activity Blood Test for Rheumatoid (204119) (Formerly Vectra DA Blood Test for Rheumatoid ) Medical Benefit Effective Date: 01/01/17 Next Review Date: 09/19 Preauthorization No Review
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationWhat I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationCHAPTER 4. S. Hirata 1, 2 L. Dirven 1 Y. Shen 3 M. Centola 4 G. Cavet 3 W.F. Lems 5 Y. Tanaka 2 T.W.J. Huizinga 1 C.F. Allaart 1
CHAPTER 4. A multi-biomarker based disease activity (MBDA) score system compared to a conventional disease activity score (DAS) system in the BeSt rheumatoid arthritis (RA) study S. Hirata 1, 2 L. Dirven
More informationPREDICTIVE BIOMARKERS IN RHEUMATOID ARTHRITIS
From THE DEPARTMENT OF MEDICINE, SOLNA Karolinska Institutet, Stockholm, Sweden PREDICTIVE BIOMARKERS IN RHEUMATOID ARTHRITIS Karen Hambardzumyan Stockholm 2018 All previously published papers were reproduced
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationImplementing Outcomes Goals in the Treatment of Rheumatoid Arthritis. Treating Rheumatoid Arthritis To Target
Implementing Outcomes Goals in the Treatment of Rheumatoid Arthritis Treating Rheumatoid Arthritis To Target Max Hamburger, MD May 3, 2012 Sandestin Hilton Sandestin, FL Disease Course of RA RA is a chronic
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationRheumatoid Arthritis. Ajay Bhatia Rheumatology Consultant Hillingdon Hospital
Rheumatoid Arthritis Ajay Bhatia Rheumatology Consultant Hillingdon Hospital ajay.bhatia@thh.nhs.uk Rheumatoid Arthritis When to refer to secondary care? Why early referral is beneficial for the patient?
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationOPEN ACCESS EXTENDED REPORT. Clinical and epidemiological research
OPEN ACCESS 1 Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 3 Department
More informationSupplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationRonald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden
Ronald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden Disclosures Research Grants: AbbVie, Amgen, BMS, GSK, Pfizer, Roche,
More informationM. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*
Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies RA: Update on Biologic Therapy and Step-Up or Step-Down Therapeutic Options Learning Objectives Describe the importance of remission
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationPoster Presented at the 2014 American College of Rheumatology Annual Meeting
Poster Presented at the 2014 American College of Rheumatology Annual Meeting Anne Winkler 1 James Mossell 2 Edmund MacLaughlin 3 Drew Johnson 4 J. Timothy Harrington 5 1 Winkler Medical Practice LLC, Springfield,
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationCharacteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
Rheumatol Ther (2015) 2:85 96 DOI 10.1007/s40744-015-0008-9 ORIGINAL RESEARCH Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationEthnic Minority RA Consortium (EMRAC)
Ethnic Minority RA Consortium (EMRAC) Yusuf Yazıcı, MD Assistant Professor of Medicine, New York University School of Medicine Director, Seligman Center for Advanced Therapeutics & Behçet Syndrome Evaluation,
More informationCADTH Therapeutic Review Panel
Therapeutic Review Panel Final Recommendations Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 RECOMMENDATIONS The Therapeutic Review Panel (TRP) recommends that in adult
More informationAdrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
International Journal of Clinical Rheumatology For reprint orders, please contact: reprints@futuremedicine.com Adrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
More informationORIGINAL ARTICLE. Rheumatoid arthritis
To cite: Tanaka Y, Yamanaka H, Ishiguro N, et al. Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab:
More informationPerspective. Combination therapy in rheumatoid arthritis: always the best option? Yasmin Bata1 & Yusuf Yazici*1
Combination therapy in rheumatoid arthritis: always the best option? One of the major developments in the treatment of rheumatoid arthritis over the last decade and a half has been the realization that
More informationThe new ACR/EULAR remission criteria: rationale for developing new criteria for remission
RHEUMATOLOGY Rheumatology 2012;51:vi16 vi20 doi:10.1093/rheumatology/kes281 The new ACR/EULAR remission criteria: rationale for developing new criteria for remission Vivian P. Bykerk 1,2 and Elena M. Massarotti
More informationAxial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital
Axial Spondyloarthritis Doug White, Rheumatologist Waikato Hospital Disclosures Presentations / Consulting Abbott Laboratories AbbVie MSD Novartis Roche Clinical Trials Abbott Laboratories AbbVie Actelion
More informationThis is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced.
This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/102808/
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationComparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Harrold et al. Arthritis Research & Therapy (2016) 18:280 DOI 10.1186/s13075-016-1179-7 RESEARCH ARTICLE Open Access Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients
More informationPros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity
Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Daniel E Furst MD University of California in Los Angeles University of Washington University of Florence
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationThe Journal of Rheumatology Volume 41, no. 2
The Volume 41, no. 2 Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study Edward C. Keystone,
More informationTREAT-TO-TARGET IN RHEUMATOID ARTHRITIS
TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all
More informationPsoriatic Arthritis: New and Emergent Therapies
Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationThe new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic?
RHEUMATOLOGY Rheumatology 2012;51:vi10 vi15 doi:10.1093/rheumatology/kes280 The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic? Vivian P. Bykerk 1,2 and
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION
Arthritis Care & Research Vol. 63, No. 1, January 2011, pp 128 134 DOI 10.1002/acr.20331 2011, American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab
More informationTreat to a Target The New Paradigm in the Management of RA. Boulos Haraoui, MD FRCPC Université de Montréal Institut de rhumatologie de Montréal
Treat to a Target The New Paradigm in the Management of RA Boulos Haraoui, MD FRCPC Université de Montréal Institut de rhumatologie de Montréal Disclosure Dr Boulos Haraoui Advisor/Research Grants/Speakers
More informationOpen Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal.
Send Orders for Reprints to reprints@benthamscience.net 58 The Open Rheumatology Journal, 2013, 7, 58-63 Open Access The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28
More information2010 Annual Meeting of the Canadian Rheumatology Association February 3 to 6, Quebec City, Quebec. Copyright. Not for Sale or Commercial Distribution
21 Annual Meeting of the Canadian Rheumatology Association February 3 to 6, Quebec City, Quebec Copyright In February 21, Quebec City hosted the annual meeting of the Canadian Rheumatology Association
More informationSmolen et al. Arthritis Research & Therapy (2015) 17:157 DOI /s
Smolen et al. Arthritis Research & Therapy (215) 17:157 DOI 1.1186/s1375-15-671-9 RESEARCH ARTICLE Open Access Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria
More informationTechnology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed Technology
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationGrigorios T. Sakellariou, 1 Athanasios D. Anastasilakis, 2 Ilias Bisbinas, 3 Anastasios Gketsos, 4 and Charalampos Berberidis 1. 1.
ISRN Rheumatology Volume 2013, Article ID 907085, 4 pages http://dx.doi.org/10.1155/2013/907085 Clinical Study Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying
More informationTofacitinib versus Methotrexate in Rheumatoid Arthritis
The new england journal of medicine original article Tofacitinib versus in Rheumatoid Arthritis Eun Bong Lee, M.D., Roy Fleischmann, M.D., Stephen Hall, M.D., Bethanie Wilkinson, Ph.D., John D. Bradley,
More informationSpA non-radiografica: fase precoce di spondilite anchilosante o altro?
Rheumatology Department of Lucania, S. Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Ignazio Olivieri Disclosures
More information1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background
1.0 Abstract Title Assessment of the safety of adalimumab in rheumatoid arthritis (RA) patients showing rapid progression of structural damage of the joints, who have no prior history of treatment with
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Summit Medical Group. Standardizing Protocols and Educating Providers
Best Practices in Managing Patients with Rheumatoid Arthritis Summit Medical Group Standardizing Protocols and Educating Providers Organizational Profile Summit Medical Group, established in 1929, is the
More informationNewer classification criteria 2010:How adequate is this to classify Rheumatoid Arthritis?
Newer classification criteria 2010:How adequate is this to classify Rheumatoid Arthritis? DR MD MATIUR RAHMAN MBBS, MD, FCPS, FACR, Fellow APLAR Associate Professor, Medicine SSMC & Mitford Hospital New
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationRecommendations for RA management: what has changed?
The 2016 Update of the EULAR Recommendations for RA management: what has changed? Baltics Rheumatology Conference Vilnius, September 21-22 Prof. Diego Kyburz University Hospital of Basel Switzerland Multiple
More informationValidation of a Novel Multibiomarker Test to Assess Rheumatoid Arthritis Disease Activity
Arthritis Care & Research Vol. 64, No. 12, December 2012, pp 1794 1803 DOI 10.1002/acr.21767 2012, American College of Rheumatology ORIGINAL ARTICLE Validation of a Novel Multibiomarker Test to Assess
More informationEfficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
To cite: Fleischmann RM, Huizinga TWJ, Kavanaugh AF, et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2016;2:e000262. doi:10.1136/rmdopen-2016-000262
More informationDrug selection in Rheumatoid Arthritis
Drug selection in Rheumatoid Arthritis PROFESSOR KHAN ABUL KALAM AZAD PROFESSOR, DEPARTMENT OF MEDICINE DHAKA MEDICAL COLLEGE Rheumatoid arthritis Autoimmune disease Onset generally occurs between 30 and
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationintolerance to tumour necrosis
To cite: Nash P, Behrens F, Orbai A-M, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic diseasemodifying antirheumatic drugs (cdmards) in patients with active psoriatic
More informationDr Tracey Kain. Associate Professor Ed Gane
Associate Professor Ed Gane New Zealand Liver Transplant Unit Auckland Dr Tracey Kain Consultant Rheumatologist Grace Orthopaedic Centre Tauranga Hospital Tauranga 7:00-7:55 Abbvie Breakfast Session 1.
More informationIdentifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 4-26-2016 Identifying factors associated with concordance with the American College
More informationABSTRACT. Keywords: Clinical efficacy; Infliximab; Interleukin-6; Prognostic serum marker; Rheumatoid arthritis ORIGINAL RESEARCH
Rheumatol Ther (2016) 3:155 166 DOI 10.1007/s40744-015-0022-y ORIGINAL RESEARCH Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION TOFACITINIB (Xeljanz Pfizer Canada Inc.) Indication: Rheumatoid Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be listed, in combination
More informationNIHR Innovation Observatory Evidence Briefing: November 2017
NIHR Innovation Observatory Evidence Briefing: November 2017 Upadacitinib for adults with moderate to severe active rheumatoid arthritis after conventional synthetic disease-modifying anti-rheumatic drugs
More informationThe effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic
More informationABSTRACT ORIGINAL RESEARCH
https://doi.org/10.1007/s40744-018-0113-7 ORIGINAL RESEARCH Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan
More informationEULAR UCB, Inc. All rights reserved. For unsolicited request only.
1 EULAR 213 2 CZP in AxSpA Effects of certolizumab pegol (CZP) on the signs and symptoms of AxSpA at week 24 (RAPID-AxSpA) 3 RAPID-AxSpA: Ongoing 24-week trial in adult patients with active AxSpA according
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationEfficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
Downloaded from http://ard.bmj.com/ on May 2, 216 - Published by group.bmj.com Clinical and epidemiological research EXTENDED REPORT Efficacy and safety of ascending methotrexate dose in combination with
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Commercial Medical Benefit Drug Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHA031 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE...
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More informationSIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect
SIMPONI Solution for Injection in a pre-filled syringe Solution for Injection in a pre-filled pen, SmartJect PRODUCT INFORMATION NAME OF THE MEDICINE Golimumab (rmc) CAS Registry Number: 476181-74-5 DESCRIPTION
More informationHorizon Scanning Research & Intelligence Centre. Baricitinib for moderate to severe rheumatoid arthritis. May 2015 SUMMARY NIHR HSRIC ID: 5270
May 2015 Horizon Scanning Research & Intelligence Centre Baricitinib for moderate to severe rheumatoid arthritis SUMMARY NIHR HSRIC ID: 5270 This briefing is based on information available at the time
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More information